Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more
Formycon AG (FYB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.017x
Based on the latest financial reports, Formycon AG (FYB) has a cash flow conversion efficiency ratio of 0.017x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€6.99 Million) by net assets (€408.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Formycon AG - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Formycon AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Formycon AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Formycon AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Almonty Industries Inc
OTCQX:ALMTF
|
-1.264x |
|
CoAsia Microelectronics
TWO:8096
|
-0.504x |
|
Enity
ST:ENITY
|
-0.044x |
|
TLB Co. Ltd.
KQ:356860
|
0.049x |
|
Suzhou Jin Hong Shun Auto Parts Co Ltd Class A
SHG:603922
|
-0.006x |
|
Friend Co Ltd
SHG:605050
|
N/A |
|
Tianjin Tianyao Pharmaceuticals Co Ltd
SHG:600488
|
0.003x |
|
Guangdong Chant Group Inc
SHE:002616
|
0.235x |
Annual Cash Flow Conversion Efficiency for Formycon AG (2009–2024)
The table below shows the annual cash flow conversion efficiency of Formycon AG from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €461.84 Million | €-23.22 Million | -0.050x | -156.68% |
| 2023-12-31 | €502.75 Million | €-9.85 Million | -0.020x | +63.23% |
| 2022-12-31 | €356.58 Million | €-18.99 Million | -0.053x | +78.01% |
| 2021-12-31 | €55.89 Million | €-13.54 Million | -0.242x | -216.50% |
| 2020-12-31 | €68.04 Million | €-5.21 Million | -0.077x | -145.04% |
| 2019-12-31 | €48.21 Million | €-1.51 Million | -0.031x | -107.81% |
| 2018-12-31 | €33.24 Million | €13.30 Million | 0.400x | +345.01% |
| 2017-12-31 | €25.54 Million | €-4.17 Million | -0.163x | +32.29% |
| 2016-12-31 | €20.89 Million | €-5.04 Million | -0.241x | -1260.19% |
| 2015-12-31 | €24.87 Million | €517.00K | 0.021x | +981.57% |
| 2014-12-31 | €13.64 Million | €-32.17K | -0.002x | +99.83% |
| 2013-12-31 | €12.25 Million | €-16.65 Million | -1.359x | -368.19% |
| 2012-12-31 | €4.26 Million | €2.16 Million | 0.507x | +6644.70% |
| 2011-12-31 | €5.14 Million | €38.60K | 0.008x | +101.07% |
| 2010-12-31 | €4.07 Million | €-2.85 Million | -0.700x | +8.21% |
| 2009-12-31 | €640.00K | €-487.93K | -0.762x | -- |